Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, scientists have uncovered details into how normal RAS interacts with mutated RAS and other proteins in living cells for the first time. The findings could aid in the development of better RAS-targeted cancer therapeutics.